Helen Bronte-Stewart, MD
Clinical Neurophysiology · Stanford, CANPI 1295786804
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (59.4%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. Medtronic accounts for 75.3% of it on its own, with 4 other manufacturers making up the rest. Reporting peaked in 2020 at $4,045 and has fallen 98.9% since, to $46 in 2025.
Across 13 payments — averaging $507.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$5K
- Genentech USA, Inc.$1K
- Neurocrine Biosciences, Inc.$125
- Supernus Pharmaceuticals, Inc.$63
- Cala Health, Inc.$20
Across 104 payments — averaging $6448.93 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Medtronic$453K
- Boston Scientific$218K
What the payments were for
- Consulting fees$1,86528%
- Speaking & faculty fees$3,92059%
- Food & beverage$81112%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 9 | $4,968 |
| Genentech USA, Inc. | 1 | $1,420 |
| Neurocrine Biosciences, Inc. | 1 | $125 |
| Supernus Pharmaceuticals, Inc. | 1 | $63 |
| Cala Health, Inc. | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Percept$3,920
- ACTIVA$770
- PERCEPT PC BRAINSENSE$139
- INGREZZA$125
How this compares
$6,596 in reported general payments places this provider in the 75th percentile of 49 clinical neurophysiology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Carbidopa-Levodopa ErCarbidopa/Levodopa | 39 | $1,685 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 51 | $1,344 |
Paid to pharmacies, not to this prescriber.
Other clinical neurophysiology in Stanford
- Christopher LockStanford$159K
- Srikanth MuppidiStanford$150K
- Mitchell MiglisStanford$51K
- Safwan JaradehStanford$34K
- Margaret FerrisStanford$18K
- Kathleen PostonStanford$18K
- Jaime LopezStanford$1K
- Sungho ChoStanford$1K
- Felix ChangStanford$974
- Laurice YangStanford$924
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.